Amgen And AstraZeneca Announce Positive Results From Phase 3 Study Of Brodalumab (AMG 827) In Patients With Moderate-to-Severe Plaque Psoriasis

[PR Newswire] – THOUSAND OAKS, Calif. and LONDON, May 9, 2014 /PRNewswire/ — Amgen (AMGN) and AstraZeneca today announced that the Phase 3 AMAGINE-1TM study evaluating brodalumab in patients with moderate-to-severe plaque psoriasis met all primary and s more

View todays social media effects on AMGN

View the latest stocks trending across Twitter. Click to view dashboard

See who Amgen is hiring next, click here to view